scholarly journals Retraction Statement: Release of CXCL12 From Apoptotic Skeletal Cells Contributes to Bone Growth Defects Following Dexamethasone Therapy in Rats

2021 ◽  
Keyword(s):  
Bone Growth ◽  
Growth Defects ◽  
Dexamethasone Therapy

scholarly journals Release of CXCL12 from Apoptotic Skeletal Cells Contributes to Bone Growth Defects Following Dexamethasone Therapy in Rats

2020 ◽  
Vol 35 (8) ◽  
pp. 1612-1613
Author(s):  
Qian Tang ◽  
Yu‐Wen Su ◽  
Chia‐Ming Fan ◽  
Rosa Chung ◽  
Mohammadhossein Hassanshahi ◽  
...  
Keyword(s):  
Bone Growth ◽  
Growth Defects ◽  
Dexamethasone Therapy

scholarly journals Release of CXCL12 From Apoptotic Skeletal Cells Contributes to Bone Growth Defects Following Dexamethasone Therapy in Rats

2018 ◽  
Vol 34 (2) ◽  
pp. 310-326 ◽  
Author(s):  
Qian Tang ◽  
Yu-Wen Su ◽  
Chia-Ming Fan ◽  
Rosa Chung ◽  
Mohammadhossein Hassanshahi ◽  
...  
Keyword(s):  
Bone Growth ◽  
Growth Defects ◽  
Dexamethasone Therapy

Mechanisms for methotrexate chemotherapy-induced bone growth defects and protective effects of folinic acid supplementary treatment

Bone ◽  
2007 ◽  
Vol 40 (6) ◽  
pp. S87-S88
Author(s):  
C.J. Xian ◽  
J. Cool ◽  
M. Scherer ◽  
C. Macsai ◽  
C. Fan ◽  
...  
Keyword(s):  
Folinic Acid ◽  
Bone Growth ◽  
Protective Effects ◽  
Growth Defects ◽  
Supplementary Treatment ◽  
Methotrexate Chemotherapy

Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects

Bone ◽  
2007 ◽  
Vol 41 (5) ◽  
pp. 842-850 ◽  
Author(s):  
Cory J. Xian ◽  
Johanna C. Cool ◽  
Michaela A. Scherer ◽  
Carmen E. Macsai ◽  
Chiaming Fan ◽  
...  
Keyword(s):  
Bone Growth ◽  
Cellular Mechanisms ◽  
Growth Defects ◽  
Methotrexate Chemotherapy

Pathophysiology and prevention of cancer chemotherapy-induced bone growth defects

Bone ◽  
2009 ◽  
Vol 45 ◽  
pp. S103
Author(s):  
C.J. Xian ◽  
C.M. Fan ◽  
J.C. Cool ◽  
M.A. Scherer ◽  
T. King ◽  
...  
Keyword(s):  
Cancer Chemotherapy ◽  
Bone Growth ◽  
Growth Defects ◽  
Prevention Of Cancer

Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB.

1985 ◽  
Vol 3 (11) ◽  
pp. 1495-1502 ◽  
Author(s):  
P Cramer ◽  
J M Andrieu
Keyword(s):  
Complete Remission ◽  
Hodgkin's Disease ◽  
Bone Growth ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Childhood And Adolescence ◽  
Growth Defects ◽  
Clinical Stages ◽  
Mediastinal Involvement ◽  
Number Of Cycles

From April 1972 to May 1980, 72 children and adolescents (aged 5 to 19 years old, median 16) with Hodgkin's disease, clinical stages IA-IIB (IA, 18; II2A, two areas involved on the same side of the diaphragm, 23; II3+A, three areas or more, 16; IIB, 15) were prospectively treated in two successive clinical trials (H 72 and H 77). Clinical stages IA and II2A received three courses of mechlorethamine, Oncovin, procarbazine, and prednisone (MOPP) and supradiaphragmatic radiotherapy (40 Gy), and no laparotomy was performed. Clinical stages II3+A and IIB received either six cycles of MOPP (H 72), three cycles of MOPP, or three cycles of CCNU, vinblastine, procarbazine, and prednisone (CVPP) (H 77) and subsequently had a laparotomy followed by supradiaphragmatic radiotherapy and a lumboaortic field if results of laparotomy were positive. Patients without evidence of mediastinal involvement did not have mediastinal radiotherapy. At the completion of therapy, the disease in 70 of 72 patients was in complete remission (one failure, one death during treatment). Eight patients relapsed (in situ, 1; marginal, 1; nonirradiated subdiaphragmatic area, 6) after three to 57 months of complete remission (median 20 months); one patient died after relapse. There were three deaths after complete remission of the disease (infection, two; acute nonlymphocytic leukemia [ANLL], one). As of June 1984 the median follow-up was 82 months (range, 49 to 145 months), the actuarial probabilities for survival and freedom from relapse for all patients being 91.6% and 87.6%, respectively. There was no statistical difference according to clinical stage, age (greater than 15 or less than 15 years), sex, or number of cycles of chemotherapy (six or three). Bone growth defects related to radiotherapy were reduced particularly in the 29 patients who did not receive mediastinal radiotherapy. None of these patients had a mediastinal relapse. Azoospermia was the rule for the male patients studied, but young girls and young women retained reproductive integrity.

Sign in / Sign up

Export Citation Format

Share Document